Economics of Cancer Care

NCCN Panel Addresses Value-Based Care in Oncology

Wayne Kuznar

April 2015, Vol 6, No 3 - Economics of Cancer Care

Hollywood, FL—Value-based decision-making at the bedside can be fraught with obstacles, with no clear agreement on what constitutes value, and for whom. In addition, the myriad insurance plans preclude uniform treatment strategies, despite clinical pathways and guidelines intended to reduce variation in care. Finally, value is becoming more difficult to achieve in oncology as each benefit becomes more expensive, with the cost of new therapies outpacing inflation. [ Read More ]

Regorafenib in Metastatic Colorectal Cancer: High Cost with Little Benefit

Chase Doyle

March 2015, Vol 6, No 2 - Economics of Cancer Care

San Francisco, CA—According to a recent cost-effectiveness analysis, third-line therapy with regorafenib (Stivarga) in patients with previously treated metastatic colorectal cancer (CRC) far ­exceeded accepted willingness-to-pay thresholds based on incremental cost-effectiveness ratio (ICER) and quality-adjusted life-years (QALYs). Presented at the 2015 Gastrointestinal Cancers Symposium, the results showed that regorafenib provided an additional 0.04 QALYs, at a cost of $39,391. [ Read More ]

Preventing Relapse in Myeloma Carries Economic Benefits, Reduces Overall Costs

Dana Taylor

March 2015, Vol 6, No 2 - Economics of Cancer Care

San Francisco, CA—In what is believed to be the first economic analysis of disease progression of patients with myeloma, researchers found that in patients with newly diagnosed myeloma, the monthly costs are reduced by 68% between the first 4 months through 18 months, but they then rise steeply when the disease relapses. The data were presented at the 2014 American Society of Hematology meeting. [ Read More ]

Value of New Drugs for Hematologic Cancers—Improving Quality, Extending Survival

Wayne Kuznar

March 2015, Vol 6, No 2 - Economics of Cancer Care

Although often criticized as being overly expensive, innovations in drug development for hematologic malignancies meet standard benchmarks for cost-effectiveness, delivering value for their cost, suggest a team of health economics researchers led by Peter J. Neumann, ScD, Director, the Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston (Saret CJ, et al. Blood. 2015 Feb 5. Epub ahead of print). [ Read More ]

Medicaid Reimbursement Rate Has Direct Impact on Cancer Screening Rates

Rosemary Frei, MSc

October 2014, Vol 5 , No 8 - Economics of Cancer Care

Although increasing the reimbursement rate for cancer screening tests does not consistently improve the likelihood of Medicaid beneficiaries being screened for cancer, raising the rate of reimbursement for office visits does consistently increase the likelihood that they will be screened for cancer, including breast or prostate cancer, according to results of a new analysis of Medicaid claims and enrollment data. [ Read More ]

Reimbursement Reform in Oncology Must Reward for Quality of Care

Dana Butler

October 2014, Vol 5 , No 8 - Economics of Cancer Care

The current fee-for-service reimbursement model used in oncology has jeopardized value-based cancer care, according to Jeffery Ward, MD, a member of the American Society of Clinical Oncology (ASCO) Workgroup on Payment Reform. He discussed the group’s novel proposal for consolidated cancer care at the Community Oncology Town Hall during the 2014 annual meeting of ASCO. [ Read More ]